Suven Life Sciences to showcase CNS pipeline at BIO 2026 Convention in San Diego

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-4.0%1-day move

₹269.00

prior close

₹263.50

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.4+0.7+1.1+1.0-4.0-5.2-0.6+3.8+4.3+12.4+29.7+19.7——

Up moveDown movePending

AI summary

Suven Life Sciences is participating in the BIO International Convention 2026 in San Diego from June 22 to 25, with 62 pre-scheduled partnering meetings. The company will showcase its CNS clinical pipeline including Ropanicant (positive Phase 2b results for Major Depressive Disorder announced June 17), Masupirdine (Phase 3, 95 percent enrolled, for Alzheimer's agitation), Samelisant (Phase 3 for narcolepsy), and SUVN-I6107. Management is seeking out-licensing and co-development partnerships with global pharma and biotech companies.

Likely market impact

Conference participation may lead to future global licensing deals, but no immediate revenue impact. Pipeline progress remains the key catalyst.